$0
Yescarta Receives Broader FL Label Than Breyanzi; MZL Not Granted in Yescarta’s ZUMA-5 Accelerated Approval
New content: The Celltelligence team has updated their CD19 CAR-T indications table for estimated approvals and submissions following Gilead’s (Kite) announcement (see below for download).
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.
OR